同侧乳腺肿瘤事件二次保乳治疗后的10年肿瘤学结局报告
该回顾性观察研究分析了244例同侧第二原发乳腺肿瘤事件(2ndIBTE)患者接受二次保乳治疗(肿瘤切除+瘤床再照射)的长期结局,其中113例随访至少60个月。中位随访121.5个月,10年第三次IBTE无事件生存率为89%,3级及以上晚期毒性为6.2%,美容效果优良率为91.2%。
要点
- 二次保乳治疗(2ndCT)后10年第三次IBTE无事件生存率为89%[83-96]。
- 10年无区域复发生存率94%,无转移生存率89%,无病生存率78%,特异性生存率95%,总生存率94%。
- 多因素分析显示APBI高危分类(HR 2.66[1.01-7.1],p=0.049)和肿瘤大小≥20 mm(HR 2.64[1.02-6.8],p=0.045)为DFS的独立预后因素。
核心结论
- 中位随访121.5个月的长随访数据显示,2ndIBTE接受二次保乳治疗可实现再次保乳且不损害肿瘤学结局,3级及以上毒性可接受。
研究设计与样本
- 回顾性观察研究(编号F20210402152843),纳入2000年9月至2022年4月间244例接受二次保乳治疗(肿瘤切除+瘤床再照射)的2ndIBTE患者,其中113例随访至少60个月纳入分析。
主要发现
- 113例可分析患者中,第一与第二IBTE中位间隔13.5年[2-35],第二IBTE中位年龄66.2岁[31-85]。
- 第二IBTE中腺癌占77%,肿瘤大小<20 mm占86.7%,组织学分级1/2级占75%,激素受体阳性占85%,手术切缘阴性(无墨水沾肿瘤)占90.3%。
- APBI分类中高危患者21例(18.6%),Luminal A/BHer2-型占77%。
- 中位随访121.5个月[95%CI 111.7-129.6],10年第三次IBTE无事件生存率89%[83-96],10年无区域复发生存率94%[89-100],无转移生存率89%[83-96],无病生存率78%[70-87],特异性生存率95%[91-100],总生存率94%[90-99]。
- 多因素分析中,APBI高危分类(HR 2.66[1.01-7.1],p=0.049)和肿瘤大小≥20 mm(HR 2.64[1.02-6.8],p=0.045)为DFS的独立预后因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To analyze long-term oncological outcome after 2nd conservative treatment (2ndCT) for patients with ipsilateral 2nd ipsilateral breast tumor event (2ndIBTE). MATERIALS/METHODS: In this retrospective observational study (N°F20210402152843), patients with 2ndIBTE underwent 2ndCT (lumpectomy + tumor bed re-irradiation). 3rdIBTE (3rdIBTE-FS), regional relapse- (RRFS) and metastatic disease- (MD-FS) free survivals as well as disease-free (DFS), specific (SS) and overall (OS) survival were analyzed. Late toxicity was reported. RESULTS: Between 09/2000 and 04/2022, 244 patients presented a 2ndIBTE and underwent a 2ndCT. Among them, 113 pts with a minimum follow-up of 60 months were analyzed. Median time interval between 1st and 2ndIBTE was 13.5 years [2-35]. Median 2ndIBTE age was 66.2 years [31-85]. 2ndIBTE were adenocarcinomas (77 %). Tumor size was < 20 mm (86.7 %). 2ndIBTE were grade 1/2 (75 %), with positive hormonal receptor (85 %) and clear surgical margins (no ink on tumor, 90.3 %). In the APBI classification, 21 pts were high-risk (18.6 %), while 77 % were Luminal A/BHer2-. With a MFU of 121.5 months [CI95% 111.7-129.6], 10-year 3rdIBTE-FS was 89 % [83-96]. Then-year RRFS, MDFS, DFS, SS and OS were 94 % [89-100], 89 % [83-96], 78 % [70-87], 95 % [91-100] and 94 % [90 -99] respectively. In multivariate analysis, APBI classification (high-risk; HR2.66 [1.01-7.1], p = 0.049) and tumor size (≥20 mm; HR2.64 [1.02-6.8], p = 0.045) were considered independent prognostic factors for DFS.Ninety-seven late complications were observed (fibrosis 64 %) with 6.2 % G ≥ 3 late toxicity. Cosmetic outcome was excellent/good in 91.2 %. CONCLUSIONS: With long follow-up, 2ndIBTE managed with 2ndCT allows second breast preservation without oncological outcome compromise and acceptable G ≥ 3 toxicity.
引用
- Hannoun-Levi JM, Gal J, Schiappa R, et al. 10-Year oncological outcome report after second conservative treatment for ipsilateral breast tumor event. Clin Transl Radiat Oncol. 2022. PMID: 36388247. doi:10.1016/j.ctro.2022.10.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。